Marvin Johnson - 07 Feb 2025 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 07 Feb 2025
Net transaction value: -$6,870
SEC form: 4
Accepted by SEC: 11 Feb 2025, 09:17:55 UTC
Prior SEC filing: 23 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Debra A. Mohollen, Attorney-in-Fact

Key filing fact

Marvin Johnson filed Form 4 for MARINUS PHARMACEUTICALS, INC. on 11 Feb 2025.

Key facts

This page summarizes Marvin Johnson's Form 4 filing for MARINUS PHARMACEUTICALS, INC..
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 11 Feb 2025, 09:17.

Change

Previous filing in this sequence was filed on 23 Jan 2025.
Current net transaction value: -$6,870.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNS transaction

Common Stock

Disposed to Issuer

Transaction value: $2,964
Shares: -5,389
Change %: -43%
Price: $0.5500
Shares after: 7,101
Date: 07 Feb 2025
Ownership: Direct
Footnotes: F1

MRNS transaction

Common Stock

Disposed to Issuer

Transaction value: $3,906
Shares: -7,101
Change %: -100%
Price: $0.5500
Shares after: 0
Date: 11 Feb 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -10,450
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 11 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,450
Exercise price: $1.40
Footnotes: F3

MRNS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -20,900
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 11 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,900
Exercise price: $9.74
Footnotes: F3

MRNS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -32,400
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 11 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,400
Exercise price: $8.01
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Marvin Johnson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.

Footnote F2

Represents 7,101 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.

Footnote F3

Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.